STAT

STAT+: Inhibrx claims first win for long-sought immunotherapy target

STAT+: Inhibrx claims first win for long-sought immunotherapy targetWorldPing

“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

More coverage: all health news on WorldPing.

Related news